Author(s): Enrique Galang, MD, Daniel De Simon, MD
Originally published: September 20, 2014 Last updated: December 17, 2025
Jump to:

Disease/Disorder

Definition

Autonomically mediated pain (AMP) is a component of neuropathic pain controlled by the two divisions of the autonomic nervous system. Autonomically mediated pain in CRPS reflects dysregulation of the autonomic nervous system (ANS) with prominent sympathetic features and contributory parasympathetic and central mechanisms. Current guidance favors a model of autonomic imbalance together with peripheral and central sensitization.1,2

A clinically useful distinction is between sympathetically maintained pain (SMP) versus sympathetically independent pain (SIP), which can guide selection and timing of sympathetic blocks and emphasis on rehabilitation pacing.1 Sympathetically mediated pain (SMP) is identified clinically as pain that does not follow a specific dermatomal distribution but can be relieved through sympathetic efferent blockade.3 In contrast, sympathetically independent pain (SIP) is unaffected by the activity of sympathetic efferents. This distinction between sympathetically maintained pain (SMP) versus sympathetically independent pain (SIP) can guide selection and timing of sympathetic blocks and emphasis on rehabilitation pacing.1

Etiology

Sympathetic autonomic responses to noxious stimuli result from nociceptive rather than from perceptual processes.

This supports the concept of pain and emotion in which sensory, motor, and autonomic components are partially independent processes that together shape emotional and painful experiences.4 SMP has many causes, with trauma being the most common. SMP can refer to complex regional pain syndrome (CRPS) type I (no verified nerve lesion) and type II (with verified nerve lesion), posttraumatic neuralgia, phantom limb pain, and acute herpes zoster (HZ).5

Epidemiology including risk factors and primary prevention

Incidence estimates for CRPS cluster around ~5–26 per 100,000 person‑years, with higher risk following distal radius and ankle fractures and in women. Early identification and rehabilitation correlate with better function at 6–12 months; avoid extrapolated figures implying hundreds of thousands of new U.S. cases per year.1,6

A large retrospective study in the Netherlands found CRPS most commonly affecting women between 50-70 years of age.7

Chronic courses of CRPS typically involve spontaneous occurrence, younger age, and female gender. Immobility may be an independent risk factor. Other risk factors include migraines, asthma, osteoporosis and the use of ACE inhibitors, all of which may reflect an inflammatory disease state.8 Genetics factors may play a role. The HLA-DQ1 serotype is isolated with increased frequency among patients with CRPS type 1 and there is an increased incidence of CRPS in siblings.9,10

Patho-anatomy/physiology

Though several mechanisms have been identified in both animal and human studies, the underlying pathophysiology remains unclear. Animal studies have shown that primary afferent nociceptors become sensitized to nociceptive stimuli by catecholaminergic sympathetic outflow. Human studies show sympathetic-induced catecholamine sensitivity following complete or partial nerve lesions. A1-adrenoreceptors are upregulated in the skin of CRPS II-affected limbs, potentially increasing the effects of sympathetic activation.8

In the early stages of CRPS, the sympathetic outflow to skin vasoconstrictors is inhibited, resulting in reduced perfusion in areas associated with spatial body perception, somatosensory cortex, and the limbic system. In later stages of CRPS, the cold limbs may reflect increased sympathetic nervous system (SNS) receptor sensitivity.5 Functional imaging studies exhibited increased perfusion in the motor cortex, a decrease of grey matter volume in pain-processing areas and cortical disruptions in regions associated with motor control and planning.11 In one study, the intracutaneous application of norepinephrine into a symptomatic area in patients with posttraumatic neuralgia was shown to propagate allodynia and spontaneous pain that had previously been blocked with sympathetic blockade.12 Other proposed mechanisms include: enhanced activity of osteoclasts and humoral factors and upregulation of proinflammatory mediators.13

Disease progression including natural history, disease phases or stages, disease trajectory (clinical features and presentation over time)

Autonomic vasomotor control may contribute to clinical features of disease progression, including erythema, warmth, and skin and nail changes seen in patients with CRPS. Autonomic instability typically results in sudomotor changes and hyperesthesia in the affected extremity over time. CRPS can progress from acute to dystrophic to atrophic stages with each stage lasting three to six months.

However, this historical three‑stage (acute→dystrophic→atrophic) model is oversimplified and not required for diagnosis/management. Contemporary guidance recommends individualized assessment by phenotype (e.g., warm vs cold), SMP vs SIP features, and functional barriers.1

Specific secondary or associated conditions and complications

SMP can have systemic manifestations. Organs with exclusive or predominant autonomic control are more prone to dysfunction during autonomic dysregulation. Patients with CRPS were shown to be four times more likely to have a positive head-up tilt test than age- and sex-matched peers.5

Almost all patients with CRPS for more than five years suffer from gastroparesis; the most frequent complaint being early satiety and bloating. Additionally, diarrhea, irritable bowel disease symptomatology, and constipation are present in 90% of these patients.

Red flags and differential diagnosis

Given the wide scope of associated symptoms, it is important to exclude these other primary conditions early, especially when pain is severe or atypical.

  • Infection (cellulitis, osteomyelitis), acute DVT, compartment syndrome, fracture/dislocation, Charcot arthropathy, arterial ischemia.
  • Inflammatory arthropathies; peripheral neuropathies (diabetic, entrapment, small‑fiber); radiculopathy/plexopathy; erythromelalgia; vasculitis; factitious disorder.
  • New focal neurologic deficits, progressive weakness, or bowel/bladder involvement require urgent neurologic evaluation.1,6,14

Essentials of Assessment

History

History of trauma or surgery with concomitant hyperalgesia and allodynia may indicate an autonomically mediated pain state. Fractures are the most frequent etiology. Other common triggers are sprains, contusions, and immobilization for extended periods of time. Intravenous line placement in tandem with other minor procedures have been documented to cause SMP.15

Pain is the most common reported sensory symptom. Hyperesthesia, hyperalgesia, and allodynia are also common complaints. SMP symptoms occur almost exclusively in the extremities and face. Motor, sensory, and trophic changes progress with environmental and symptom progression. Vasomotor complaints include flushing or erythema in the affected limb(s). Sudomotor signs include increased perspiration in the affected limb(s).

Physical examination

Vasomotor and sudomotor abnormalities are common presentations, with a study finding 81% of patients with CRPS having visible edema in the affected limb(s) during the acute stage.5

  • Inspection: changes in appearance of the involved area, including trophic changes, differences in hair and nail growth, muscular atrophy, deviations in skin turgor, swelling and color changes.
  • Temperature Evaluation: Palpable temperature changes may not be detectable in early disease stages (objective testing).
  • Edema: volumetric testing or bilateral circumference measurements
  • Motor Evaluation: involuntary movements, dystonia, muscle weakness, atrophy, or limited range of active motion in the involved limb(s).
  • Sensory Evaluation: A detailed sensory examination including the presence of allodynia and the anatomic pattern of any associated sensory abnormalities to light touch, deep touch, pain, and thermal stimulation.16

Imaging

Imaging is not recommended as a diagnostic tool for diagnosing autonomically mediated pain states, however it may be helpful for ruling out other processes. Plain films in CRPS may show spotty osteoporotic changes at the juxta-articular parts of bones, by four to eight weeks after onset. MRI is used to exclude other disease processes. Triple-phase bone scintigraphy (TPBS) with technetium-99m is used to diagnose CRPS with an increased tracer uptake in the mineralization phase (phase 3). (TPBS) provides variable accuracy and rarely changes management; it is not recommended as a screening or confirmatory test. Infrared thermography may help classify warm/cold phenotypes; a pragmatic side‑to‑side threshold ≈0.6°C can be used as supportive information, not as a diagnostic determinant.1,17 Electrodiagnostic studies can be effective in localizing a nerve lesion when suspected.18

Supplemental assessment tools

Traditionally, SMP is assessed clinically by pain relief following sympathetic blockade. Peripheral sympathetic pathways have multiple locations where blockade is feasible, including the subarachnoid space, epidural space, paravertebral and prevertebral regions, peripheral nerves, and endings of postganglionic axons.

Additional objective tests include thermoregulatory sweat test, silastic imprint, sympathetic skin response, and quantitative sudomotor axon reflex test. Ancillary tests are adjunctive to exclude alternatives or support phenotyping; they should not be used in isolation to ‘rule in’ or ‘rule out’ CRPS. Autonomic testing (head‑up tilt, QSART, SSR, HRV) has limited sensitivity/specificity for CRPS per se and is best reserved for comorbid orthostatic/sudomotor syndromes or research protocols.1

The Budapest criteria is specifically used for the clinical diagnosis of CRPS.8

  • Continuing pain disproportionate to any inciting event
  • Must report at least one symptom in three of the four following categories
  • Must report at least one sign at time of evaluation in two or more of the following categories:
    • Sensory: hyperalgesia (to pinprick) and/or allodynia (to light touch, deep somatic pressure, joint movement)
    • Vasomotor: temperature asymmetry and/or skin color changes and/or skin color asymmetry
    • Sudomotor or edema: edema and/or sweating changes and/or sweating asymmetry
    • Motor or trophic: decreased range of motion and/or motor dysfunction (weakness, tremor, dystonia) and/or trophic changes (nail, hair, skin)
  • There is no other diagnosis that better explains the signs and symptoms.

Early predictions of outcomes

Overall, approximately 60-70% of patients will experience resolution of symptoms at 12 months. Some early outcome predictors may include vocational or psychologic status, medication consumption, family relationships, emotional distress, pain intensity, and objective initial physiotherapeutic response measures. Specifically, high pain intensity has been cited as an indicator of negative outcomes. Additionally, if patients have motor dysfunction during the early stages of the disease course the majority will continue to have motor dysfunction.10

Typical tools used for assessment include the McGill Pain Questionnaire-Short Form, Beck Depression Inventory, Treatment Outcomes in Pain Survey, State-Trait Anxiety Inventory, and Pain Disability Index.

Social role and social support system

There are many support groups available for patients with autonomically mediated pain. The proliferation of social media has increased awareness and accessibility to support groups. The American RSPHope website (RSDhope.org) currently lists 146 support groups nationally throughout the U.S.

Rehabilitation Management and Treatments

Available or current treatment guidelines

Management should prioritize early function, edema control, desensitization, and education, supported by time‑limited pharmacologic and interventional options. A practical approach is to (1) relieve pain/edema sufficiently to enable high‑value rehabilitation, (2) address SMP physiology where present, and (3) reassess at 4–6‑week intervals with objective functional metrics.1,19

Concurrent physical and occupational therapy, and pain management are recommended for pain and edema control. Psychological support to assess patient motivation and adherence to and tolerance of therapies. Clinical education is important for recognition of condition at earlier stages and improved adherence. The average time to diagnose CRPS has been estimated by various authors at a range from nine months to three years.

Pharmacologic management (typical adult dosing; adjust for age/comorbidity)

  • NSAIDs/acetaminophen: short courses for nociceptive flares (e.g., ibuprofen 400–600 mg q6–8h PRN; acetaminophen ≤3–4 g/day; lower if hepatic risk).1
  • Neuropathic agents: gabapentin 300 mg qHS → 300 mg TID (target 900–3,600 mg/day); pregabalin 50 mg BID → 75–150 mg BID; duloxetine 30 mg qd → 60 mg qd; amitriptyline 10–25 mg qHS → 25–75 mg qHS.1,19
  • Early corticosteroids (best within weeks–few months of onset): prednisolone 20–40 mg/day ×1–2 wks then taper over 4–8 wks; an RCT showed 20 mg non‑inferior to 40 mg for early CRPS‑I.20,21
  • Bisphosphonates: where available, neridronate 100 mg IV daily ×4 (total 400 mg) shows meaningful pain/functional gains, especially when given early; alternatives include pamidronate 60–90 mg IV ×1 or alendronate 40 mg PO daily ×8 wks.22,23
  • Ketamine (sub‑anesthetic infusions): short‑term analgesic benefit in selected refractory cases; protocol heterogeneity and durability vary; integrate with rehab; discuss adverse effects.23,24
  • Topicals: lidocaine 5 % patches for focal allodynia; consider compounded ketamine/amitriptyline in specialist settings.1
  • Opioids: reserve for rescue/bridge (if at all) within a functional‑goal framework; reassess early and taper if no functional gain.1

Sympathetic procedures (for SMP‑predominant limbs)

  • Diagnostic stellate ganglion (upper limb) or lumbar sympathetic block (lower limb) with local anesthetic to facilitate same‑day/next‑day rehabilitation sessions.1,2
  • If ≥50 % short‑term relief enabling therapy, consider a short series (up to 2–3) spaced 1–2 weeks apart while escalating PT/OT; stop if benefit wanes.1
  • Adjuncts: limited RCT/series suggest botulinum toxin at the lumbar sympathetic chain may prolong analgesia; confirmatory trials are needed.1

Neuromodulation

Consider dorsal root ganglion (DRG) stimulation for focal distal CRPS with refractory pain and functional limitation; sustained pain/functional benefits are reported across cohorts and systematic reviews.21,25

Conventional SCS remains an option for more diffuse patterns. Emerging closed‑loop and 10 kHz SCS platforms have regulatory clearances for chronic neuropathic back/leg pain with improving durability data; CRPS‑specific trials are ongoing—set expectations regarding trial‑to‑implant success, reprogramming needs, and device longevity.1,21

Rehabilitation and psychological interventions

  • Graded motor imagery (left/right discrimination → explicit motor imagery → mirror therapy) and sensorimotor retraining; effect sizes vary but support use in comprehensive programs.1,6
  • Exposure‑in‑vivo for fear‑avoidance, with functional hierarchies anchored to patient goals; pair with pacing/flare plans.1
  • Edema control (compression/elevation/manual lymph), progressive loading and ROM, proprioceptive training, cardiovascular conditioning, and vocational/ADL simulations.1,19

Prognosis and follow‑up

Earlier diagnosis and active rehabilitation are associated with better 6–12‑month function and lower chronic disability. Track outcomes every 4–6 weeks (pain intensity, LEFS/DASH as appropriate, ROM, edema, sensory thresholds, goal attainment). Escalate to interventional or neuromodulatory options only after plateau despite adherence and optimized pharmacologic therapy.1,19

Practical pathway (clinic flow)

  • Confirm Budapest criteria; document phenotype (warm/cold; SMP/SIP).
  • Exclude red flags/differentials; only targeted labs/imaging as indicated.
  • Start function‑first rehab + desensitization + edema control; add neuropathic agents/NSAIDs as needed; consider short‑course steroids if early CRPS.
  • If SMP‑predominant and rehab limited by pain, consider diagnostic sympathetic block linked to rehab session; repeat up to 2–3 if enabling.
  • Insufficient progress at 6–12 weeks: consider bisphosphonate (where accessible), ketamine in refractory cases, and evaluate for DRG/SCS in carefully selected patients.
  • Maintain outcome tracking; build a flare‑management plan; coordinate multidisciplinary care.1,2,19,21

At different disease stages

In the acute phase, early therapies include gentle active range of motion exercises, stretching, and strengthening. The predominant role of these therapies is to prevent the decreased joint and tendon range of motion that can lead to atrophy.26 Manage edema with limb elevation, retrograde massage, and, rarely, diuresis. Orthostatic hypotension management may include compression garments, lifestyle changes (e.g., alcohol abstinence, improved fluid intake), and/or pharmacologic agents, including midodrine, pyridostigmine, epoetin, or caffeine.

Advance rehabilitation to stress loading, isotonic strengthening, desensitization, and aerobic conditioning. Adding recreational and vocational therapy can encourage use. Psychologic and/or coping factors may require attention; cognitive-based therapies are used most frequently. Formal psychological assessment is recommended for patients with CRPS with symptoms for more than six to eight weeks.27 Graded motor imagery has also been shown in a small randomized controlled trial to be effective in patients with type I CRPS, although the mechanisms are unclear.28

Topical agents have shown some transient relief, without clear impact on progression. CRPS is hypothesized to involve increased glutamate output that act on the NMDA receptors on second order neurons of the spinal cord. This results in central sensitization.29 The NMDA antagonistic effects of ketamine can reduce allodynia in patients with CRPS8 when used topically with less side effects than parenterally administered ketamine. Ketamine infusions appear to produce adequate short-term pain relief, less than three months.30 Systemic infusions with ketamine at subanesthetic doses and phentolamine have been used.31

Interventional treatments may include one or multiple diagnostic ganglion blocks followed by a more permanent lesioning with radio frequency or administration of a neurolytic agent. Sympathetic blocks can be used early in treatment of CRPS when combined with Physical Therapy.15 Ablation of the sympathetic ganglion is rarely performed at this time. Conventional spinal stimulators have been proven effective in refractory cases of CRPS in several clinical trials, but recent studies suggest that dorsal root ganglion (DRG) stimulators tend to have better coverage of the affected area and are better tolerated by patients.32,33 Peripheral nerve stimulation should be considered for CRPS II with symptoms in the distribution of a single peripheral nerve unresponsive to other modalities. It should not be considered in patients with CRPS involving an entire limb or extension to the trunk.34 Interventional modalities have their own set of risks, which may eclipse the risks of conservative management.

Coordination of care

Coordination of care between physiatry, pain specialists, neurology, primary care, behavioral health professionals, and physical, occupational, recreational, and vocational therapy is necessary. Effective coordination of care has been shown to increase patient motivation.35 Early diagnosis is key to the best outcomes. Patients can improve through treatment measures ranging from pharmacologic to physical and psychological measures.

Patient & family education

Patient and family education is an important tool in the multimodal approach to treating autonomically mediated pain.31 Outline of treatment modalities along with time frames of the various stages provide for improved clarity and expectations. Maintenance of a pain and functional diary can help monitor pain progression and treatment effect.

Emerging/unique interventions

Objective and survey-based outcome measures currently exist for SMP. Grip strength via dynamometry is commonly used in type I CRPS; the McGill Pain Questionnaire-Short Form is used in chronic pain states, including neuropathic pain, and involves 22 items with pain descriptions rated on a 10-point scale. Brush allodynia is typically used for patients with type I CRPS. The visual analog scale measures disease progression and response to treatments and/or therapies.

After adequate pain control, a case report of dry needling and intra-articular joint injections helped improve motor recovery.16 Immunosuppressants, such as mycophenolate, have shown promise in decreasing skin sensitivity, improving function and quality of life in a subgroup of CRPS patients.36 Amputations have not shown to decrease the incidence of pain or recurrence of CRPS.

Translation into practice: practice “pearls”/performance improvement in practice (PIPs)/changes in clinical practice behaviors and skills

Obtaining a thorough history may provide clinical oversight. Trophic, sudomotor, and/or vasomotor changes, especially after a documented peripheral nerve injury, highly implicates a complex regional pain state. Phantom limb pain may have autonomic findings. Variability/inconsistency in the formal and observational testing may require re-examination. However, given the chronic and progressive nature of most SMP states, the likelihood of remission or cure with a given intervention should be weighed against the likelihood of improvement with conservative treatment.

Cutting Edge/Emerging and Unique Concepts and Practice

Animal models have shown allodynic behavior differences among different strains of rats with similar spinal nerve lesioning. It has been postulated that there may be genetically specific predispositions to sympathetically maintained allodynic behavior and possible differences in adrenergic receptor expression. Patients that fail medical management and lifestyle changes are typically candidates for interventional procedures (e.g., ganglion blockade, intravenous dissociative infusions). For those patients whose symptoms cannot be controlled through the aforementioned techniques, the implantation of a spinal cord stimulator or a peripheral nerve stimulator may provide long-lasting control of symptoms; however, the effectiveness of the spinal cord stimulator in controlling type I CRPS symptoms declines over time.37 Intrathecal delivery of analgesics by way of an implanted pump has been used as well. Other emerging treatment modalities include hyperbaric oxygen therapy, botulinum toxin-A, and low-dose Naltrexone.15

Gaps in the Evidence-Based Knowledge

Although multiple animal models have shown that afferent neurons can develop adrenergic sensitization after inflammation, trauma, or infection, the exact mechanism of adrenoreceptor sensitization in humans is not clear.

Appendix: CRPS at a Glance (2025)

One‑page quick reference.

Budapest checklist 3

  • Continuing pain disproportionate to inciting event.
  • ≥1 symptom in ≥3 of 4 categories; ≥1 sign in ≥2 categories (sensory, vasomotor, sudomotor/edema, motor/trophic).
  • Exclude better alternative diagnoses.

Red flags/differentials1,38,39

  • Infection, DVT, compartment syndrome, fracture/dislocation, Charcot, arterial ischemia.
  • Inflammatory arthritides; neuropathies; radiculopathy/plexopathy; erythromelalgia; vasculitis; factitious.
  • Sudden neuro deficits or bowel/bladder involvement → urgent neuro eval.

First‑line meds & typical doses3,28,35,39,40

  • NSAIDs/acetaminophen (short courses).
  • Gabapentin 300 mg qHS → 300 mg TID (target 900–3,600 mg/day); pregabalin 50 mg BID → 75–150 mg BID; duloxetine 30 mg qd → 60 mg qd; amitriptyline 10–25 mg qHS → 25–75 mg qHS.
  • Prednisolone 20–40 mg/day ×1–2 wks then taper 4–8 wks (early CRPS).
  • Bisphosphonates (e.g., neridronate 100 mg IV daily ×4; pamidronate 60–90 mg IV ×1; alendronate 40 mg PO daily ×8 wks).
  • Topicals (lidocaine 5 %); consider compounded ketamine/amitriptyline.

Block algorithm (SMP)3,41

  • Confirm SMP features (vasomotor/sudomotor changes, allodynia).
  • Diagnostic stellate or lumbar sympathetic block linked to rehab session.
  • If ≥50 % short‑term relief enabling therapy → up to 2–3 blocks (1–2 wk intervals).
  • Minimal benefit → manage as SIP; consider bisphosphonate/ketamine; evaluate for neuromodulation if refractory.

Rehab ladder3,39

  • Tier 1 (0–2 wks): edema control, gentle AROM, desensitization, breathing/relaxation.
  • Tier 2 (2–6 wks): graded motor imagery → mirror therapy; sensorimotor retraining; isometrics; gradual loading.
  • Tier 3 (6–12 wks): progressive resistance; proprioception; exposure‑in‑vivo; aerobic; ADL/vocational tasks.
  • Tier 4 (≥3 mos): work/sport‑specific return; flare plan; outcome tracking (pain, LEFS/DASH, ROM, edema, goals).

References

  1. Harden RN, McCabe CS, Goebel A, et al. Complex Regional Pain Syndrome: Practical Diagnostic and Treatment Guidelines, 5th Edition. Pain Med. 2022;23(Suppl 1):S1–S53. doi:10.1093/pm/pnac046.
  2. Gharibo C, Hirsch JA, Atluri S, et al. Diagnostic Guidance for Chronic Complex Regional Pain Syndrome (CRPS) Type I and II. Pain Physician. 2025;28(4):E391–E436.
  3. Loeser J, Butler S, Chapman CR, Turk D. Bonica’s Management of Pain. 3rd ed.
  4. Petersen, P. B., Mikkelsen, K. L., Lauritzen, J. B., & Krogsgaard, M. R. (2018). Risk Factors for Post-treatment Complex Regional Pain Syndrome (CRPS): An Analysis of 647 Cases of CRPS from the Danish Patient Compensation Association. Pain Practice, 18(3), 341-349. doi:10.1111/papr.12610
  5. Birklein F, O’Neill D, Schlereth T. Complex regional pain syndrome An optimistic perspective. Neurology Jan 2015, 84 (1) 89-96; DOI: 10.1212/WNL.0000000000001095
  6. Noh C, Park J, Kim H, et al. Diagnostic Performance of Infrared Thermography, QSART, and 3‑Phase Bone Scintigraphy for Complex Regional Pain Syndrome Diagnosis: A Retrospective Observational Study. Diagnostics (Basel). 2025;15(7):1653. doi:10.3390/diagnostics15071653.
  7. Goh EL, Chidambaram S, Ma D. Complex regional pain syndrome: a recent update. Burns & Trauma. 2017;5:2. doi:10.1186/s41038-016-0066-4.
  8. Drummond PD, Drummond ES, Dawson LF, et al. Upregulation of a1-adrenoceptors on cutaneous nerve fibres after partial sciatic nerve ligation and in complex regional pain syndrome type II. Pain 2014; 155:606–616.
  9. Kemler MA, van de Vusse AC, van den Berg-Loonen EM, et al. HLA-DQ1 associated with reflex sympathetic dystrophy. Neurology 1999; 53:1350.
  10. Johnson, S., Cowell, F., Gillespie, S., & Goebel, A. (2022). Complex regional pain syndrome what is the outcome? – A systematic review of the course and impact of CRPS at 12 months from symptom onset and beyond. European journal of pain (London, England), 26(6), 1203–1220.
  11. Zhao, J. L., Wang, Y. J., & Wang, D. J. (2018). The Effect of Ketamine Infusion in the Treatment of Complex Regional Pain Syndrome: a Systemic Review and Meta-analysis. Current Pain and Headache Reports, 22(2). doi:10.1007/s11916-018-0664-x
  12. Hohenschurz-Schmidt DJ, Calcagnini G, Dipasquale O, Jackson JB, Medina S, O’Daly O, O’Muircheartaigh J, de Lara Rubio A, Williams SCR, McMahon SB, Makovac E, Howard MA. Linking Pain Sensation to the Autonomic Nervous System: The Role of the Anterior Cingulate and Periaqueductal Gray Resting-State Networks. (2020) Front. Neurosci.14:147. doi: 10.3389/fnins.2020.00147
  13. Birbaumer N, Sherman R. Phantom limb pain. In:International Association for the Study of Pain, Vol. VIII, No. 3 6/2000. de Mos M, de Bruijn AG, Huygen FJ, Dieleman JP, Stricker BH, Sturkenboom MC. The incidence of complex regional pain syndrome: a population-based study.Pain. 2007;129(1-2):12-20.
  14. Sandroni P, et al. Autonomic testing and clinical features in RSD/CRPS. Neurology. 1998;51:1908–1916.
  15. Dey S, Hunter CW, Davis T. Complex Regional Pain Syndrome. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 (updated).
  16. Shokouhi, M., Clarke, C., Morley-Forster, P., Moulin, D. E., Davis, K. D., & Lawrence, K. S. (2018). Structural and Functional Brain Changes at Early and Late Stages of Complex Regional Pain Syndrome. Journal of Pain, 19(2), 146-157. doi:10.1016/j.jpain.2017.09.007
  17. Kalita J, Kumar S, Misra UK. Prednisolone 20 mg versus 40 mg in complex regional pain syndrome‑I: An open‑label randomized controlled trial. J Clin Neurosci. 2023;113:54–60. doi:10.1016/j.jocn.2023.06.006.
  18. Terkelsen AJ, Mølgaard H, Hansen J, Finnerup NB, Krøner K, Jensen TS. Heart rate variability in complex regional pain syndrome during rest and mental and orthostatic stress.Anesthesiology. 2012;116(1):133-146.
  19. Candan B, et al. Comparative Analysis of Temperature Variations Following Lumbar Sympathetic Block in CRPS. J Clin Med. 2025;14(6):2060.
  20. Varenna M, Adami S, Rossini M, et al. Treatment of complex regional pain syndrome type I with neridronate: A randomized, double‑blind, placebo‑controlled study. Rheumatology (Oxford). 2013;52(3):534–542. doi:10.1093/rheumatology/kes312
  21. Zhu H, Zhang Y, Guo Y, et al. Efficacy and Safety of Pharmacological Treatment in Patients with Complex Regional Pain Syndrome: A Systematic Review and Meta‑analysis. J Pain Res. 2024;17:1591–1618. doi:10.2147/JPR.S474451.
  22. Lii TR, Shanthanna H, Ladha KS, et al. Ketamine for Complex Regional Pain Syndrome. Curr Pain Headache Rep. 2023;27(5):269–298. doi:10.1007/s11916-023-01080-3.
  23. Mattie R, Marshall B, Deer T, et al. Spinal Cord Stimulation and Dorsal Root Ganglion Stimulation for Complex Regional Pain Syndrome: A Systematic Review of Randomized Controlled Trials. Pain Pract. 2024;24(9):867–885. doi:10.1111/papr.13342.
  24. CMS LCD: Autonomic Function Tests (L33609). Accessed 2025
  25. Dey S, Hunter CW, Davis T. Complex Regional Pain Syndrome. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 (updated).
  26. Kemler MA, de Vet HC, Barendse GA, van den Wildenberg FA, van Kleef M. Effect of spinal cord stimulation for chronic complex regional pain syndrome type I: five-year final follow-up of patients in a randomized controlled trial.J Neurosurg. 2008;108(2):292-298.
  27. Baron R, Schattschneider J. The autonomic nervous system and pain. In:Handbook of Clinical Neurology, Vol. 81 (3rd series). 363-382.
  28. Adams S, et al. Complex regional pain syndrome type II with sympathetic ganglion blockade and electrodiagnostic confirmation: a case report.Pain. 14(4 Suppl).
  29. Eldufani J, Elahmer N, Blaise G. A medical mystery of complex regional pain syndrome. Heliyon. 2020 Feb 19;6(2):e03329. doi: 10.1016/j.heliyon.2020.e03329. PMID: 32149194; PMCID: PMC7033333.
  30. De Rooij AM, de Mos M, Sturkenboom MC, et al. Familial occurrence of complex regional pain syndrome. Eur J Pain 2009; 13:171–177.
  31. Dayan, L., Hochberg, U., Nahman-Averbuch, H., Brill, S., Ablin, J. N., & Jacob, G. (2018). Increased Sympathetic Outflow Induces Adaptation to Acute Experimental Pain. Pain Practice, 18(3), 322-330. doi:10.1111/papr.12606
  32. Lee, J. W., Lee, S. K., & Choy, W. S. (2018). Complex Regional Pain Syndrome Type 1: Diagnosis and Management. Journal of Hand Surgery-Asian-Pacific Volume, 23(1), 1-10. doi:10.1142/s2424835518300013
  33. Rockett, M. Diagnosis, mechanisms and treatment of complex regional pain syndrome. Curr Opin Anaesthesiol 27: 494-500, 2014
  34. Chmiela MA, Hendrickson M, Hale J, Liang C, Telefus P, Sagir A, Stanton-Hicks M. Direct Peripheral Nerve Stimulation for the Treatment of Complex Regional Pain Syndrome: A 30-Year Review. Neuromodulation. 2021 Aug;24(6):971-982. doi: 10.1111/ner.13295. Epub 2020 Oct 24. PMID: 33098229.
  35. Finch PM, Knudsen L, Drummond PD. Reduction of allodynia in patients with complex regional pain syndrome: a double-blind placebo-controlled trial of topical ketamine.Pain. 2009;146(1-2):18-25.
  36. Goebel, A., Lewis, S., Phillip, R., & Sharma, M. (2018). Dorsal Root Ganglion Stimulation for Complex Regional Pain Syndrome (CRPS) Recurrence after Amputation for CRPS, and Failure of Conventional Spinal Cord Stimulation. Pain Practice, 18(1), 104-108. doi:10.1111/papr.12582
  37. Moseley GL. Graded motor imagery is effective for long-standing complex regional pain syndrome: a randomised control trial.Pain. 2004;108(1-2):192-198.
  38. Getson. The use of thermography in the diagnosis of CRPS: a physicians’s opinion.Pzin Practitioner. 2006;16(1).
  39. Goebel, A., Jacob, A., Frank, B., Sacco, P., Alexander, G., Philips, C., . . . Moots, R. (2018). Mycophenolate for persistent complex regional pain syndrome, a parallel, open, randomised, proof of concept trial. Scandinavian Journal of Pain, 18, 29-37. doi:10.1515/sjpain-2017-0154
  40. Schwartzman RJ, Alexander GM, Grothusen JR, Paylor T, Reichenberger E, Perreault M. Outpatient intravenous ketamine for the treatment of complex regional pain syndrome: a double-blind placebo controlled study.Pain. 2009;147(1-3):107-115.
  41. Ziegler-Graham K, MacKenzie EJ, Ephraim PL, Travison TG, Brookmeyer R. Estimating the prevalence of limb loss in the United States: 2005 to 2050.Arch Phys Med Rehabil. 2008;89(3):422‐429.

Original Version of the Topic

Darryl L. Kaelin, MD, John Scott Adams, MD. Autonomically mediated pain-autonomic pain syndromes. 9/20/2014.

Previous Revision(s) of the Topic

Michael Bruce Furman, MD, Shannon Schultz, MD, MPH, and Vivek Babaria, DO. Autonomically mediated pain-autonomic pain syndromes. 6/29/2018.

Vivek Mukherjee, MD, Antonio Quidgley-Nevares, MD, Christopher Trower, DO, Matthew Spinks, MD, Giovanni Torres, MS4, John Lee, MS4. Autonomically Mediated Pain-Autonomic Pain Syndromes. 12/14/2022.

Author Disclosures

Enrique Galang, MD
Nothing to Disclose

Daniel De Simon, MD
Nothing to Disclose